



April 10, 2026

Subject: Invitation to the 2026 Annual General Meeting of Shareholders

Dear Mukdahan International Hospital Public Company Limited

- Attachments:
1. 2025 Annual Information Statement (Form 56-1 One Report) in QR Code format.
 2. Proxy Form B and C
 3. Information on independent directors nominated to act as proxies.
 4. Guidelines for attending the shareholders' meeting via electronic media (E-AGM)
 5. The Company's Articles of Association specifically relating to shareholder meetings and voting.
 6. Auditor Information
 7. Profiles of the persons nominated to be elected as Directors to replace those who retire by rotation.
 8. Definition of Independent Director
 9. Map of the broadcasting venue for the meeting via electronic media (E-AGM)
 10. Notice of Personal Data Protection (PDPA)

The Board of Directors' Meeting of Mukdahan International Hospital Public Company Limited ("the Company") No. 1/2026, held on February 27, 2026, resolved to convene the 2026 Annual General Meeting of Shareholders on April 30, 2026, at 1:30 PM, via electronic media (E-AGM), to consider the following agenda items.

Agenda 1: The Chairman informed the meeting.

Resolution: This agenda item is for acknowledgment only; therefore, no vote was taken.

Agenda 2: Considered and approved the Company's performance report for the year ended December 31, 2025.

Objectives and Rationale

The Company has summarized the performance results and significant changes that occurred during the fiscal year 2025. Details are available in the 2025

56-1 One Report, provided as a QR code and sent to shareholders with the meeting invitation, as detailed in Attachment 1.

Opinion of the Board of Directors

It is deemed appropriate to propose to the Annual General Meeting of Shareholders that they acknowledge the Company's performance report for the year ended December 31, 2025.

Resolution: This agenda item is for acknowledgment only; therefore, no vote was taken.

Agenda 3: Consider and approve the Company's financial statements for the year ended December 31, 2025, which have been approved by the Audit Committee and audited by the auditors.

Objectives and Rationale

This is in accordance with the Public Limited Companies Act B.E. 2535 (1992), Section 112, and Article 51 of the Company's Articles of Association, which requires the Board of Directors to prepare a balance sheet or statement of financial position and a profit and loss account that is accurate and complete as of the end of the fiscal year and present it to the shareholders at the Annual General Meeting for approval. The Board of Directors must ensure that the balance sheet and profit and loss account are audited by an auditor before presentation to the shareholders. Details are provided in the Annual Registration Statement 2025 (56-1 One Report) in the form of a QR code, which has been sent to shareholders along with the meeting invitation as Attachment 1 (appearing in Section 3: Financial Statements).

Opinion of the Board of Directors

It is recommended to propose to the Annual General Meeting of Shareholders for approval of the Company's financial statements and profit and loss statement for the year ended December 31, 2025, which have been approved by the Audit Committee and audited by the auditor.

Resolution: This agenda item requires approval by a majority vote of shareholders present and voting.

Agenda 4: Considered and approved the allocation of profits to legal reserves as required by law, and the omission of dividend payments for the Company's 2025 fiscal year.

Objectives and Rationale

To comply with the Public Limited Companies Act B.E. 2535 (1992), Section 116 and the Company's Articles of Association, Article 57, the Company must allocate a portion of its annual net profit as a legal reserve, not less than five percent (5%) of the annual net profit less any accumulated loss brought forward (if any), until this reserve reaches not less than ten percent (10%) of the registered capital. In addition to the aforementioned legal reserve, the Board of Directors may propose to the shareholders' meeting a resolution to allocate other reserves as deemed appropriate for the Company's operations. Upon approval by the shareholders' meeting, the Company may transfer other reserves, legal reserves, and share premium reserves, in that order, to offset the Company's accumulated losses.

This is to comply with Section 115 of the Public Limited Companies Act B.E. 2535 (1992) and Article 56 of the Company's Articles of Association, dividends shall not be paid from any type of funds other than profits. In the event that the Company still has an accumulated loss, no dividends shall be paid.

Opinion of the Board of Directors

It is deemed appropriate to propose to the annual general meeting of shareholders for consideration and approval of the allocation of profits to the legal reserve. In fiscal year 2025, the net profit was 1,123,183 baht, and it is therefore proposed that 56,900 baht be allocated to the legal reserve.

Opinion of the Board of Directors

The Board of Directors Meeting No. 1/2026 approved the omission of dividend payments for the Company's operating results. As of December 31, 2025, the Company had accumulated losses of 1,991,384 baht, preventing dividend distribution in accordance with Section 115 of the Public Limited Companies Act B.E. 2535 (1992) and Article 56 of the Company's Articles of Association, which prohibits dividends from sources other than profits when accumulated losses remain.

Resolution: This agenda item requires approval by a majority vote of shareholders present and voting.

Agenda 5: Consider and approve the determination of director and sub-committee remuneration for the year 2026.

Objectives and Rationale

This is to comply with the Public Limited Companies Act B.E. 2535 (1992) Section 90 and Article 37 of the Company's Articles of Association. The Company's directors are entitled to receive director remuneration from the Company in the form of monetary awards, meeting allowances, pensions, bonuses, or other benefits, as resolved by a shareholders' meeting with a vote of no less than two-thirds (2/3) of all votes cast by shareholders present at the meeting. This remuneration may be fixed at a specific amount or based on specific criteria, and may be determined for a specific term or have a perpetual effect until amended by a resolution of the shareholders' meeting. Additionally, the Company's directors are entitled to receive allowances and other benefits as stipulated in the Company's regulations.

Details of the remuneration of the Board of Directors and sub-committees for the past 3 years

List	Meeting Allowance (baht per meeting) (only for directors who attend)		
	2023	2024	2025
Board of Directors	725,000	955,000	710,000
Audit Committee	200,000	260,000	280,000
Nomination and Remuneration Committee.	350,000	100,000	100,000
Executive Committee	None	None	None
Risk Management Working Group	None	None	None
Corporate Governance and Social Responsibility Working Group	None	None	None

Details of remuneration payments to the Board of Directors and sub-committees for the year 2026 compared to the prior year are as follows.

List	Meeting Allowance	
	2026	2025
Board of Directors		
Chairman of the Board of Directors	30,000	30,000
Company Directors	20,000	20,000
Audit Committee		
Chairman of the Board of Directors	30,000	30,000
Audit Committee	20,000	20,000
Nomination and Remuneration Committee.		
Chairman of the Nomination and Remuneration Committee	30,000	30,000
Nomination and Remuneration Committee	20,000	20,000
Executive Committee	None	None
Risk Management Working Group	None	None
Corporate Governance and Social Responsibility Working Group	None	None

The Nomination and Remuneration Committee has reviewed and vetted the policies and principles for director compensation, ensuring rates are appropriate for the roles and responsibilities involved, benchmarked against comparable industries of similar size, and then presented to the Board of Directors for approval before being submitted to shareholders for consideration.

Opinion of the Board of Directors

It is deemed appropriate to propose to the Annual General Meeting of Shareholders for consideration and approval of the remuneration for the Board of Directors and Sub-Committees for the year 2026 as follows.

Remuneration of the Board of Directors and its Sub-Committees

Sequence	Position	Meeting Allowance	
		2026	2025
1.	Chairman of the Board of Directors	30,000	30,000
2.	Director	20,000	20,000

Note: Directors who are executives or salaried employees of the Company will not receive this remuneration.

Resolution: This agenda item requires approval from at least two-thirds of the total votes of shareholders attending the meeting.

Agenda 6: Consider and approve the appointment of directors to replace those retiring by rotation in 2026.

Objectives and Rationale

This is in accordance with the Public Limited Companies Act, B.E. 2535 (1992), Section 71 and Article 22 of the Company's Articles of Association. At each annual general meeting of shareholders, directors shall retire from office, with one-third (1/3) of the total number of directors stepping down. If the number of directors is not divisible by three, the number retiring shall be the closest whole number to one-third (1/3). Retiring directors are eligible for re-election.

Opinion of the Board of Directors: The directors due to retire by rotation in 2026 are as follows:

1. Mr. Boontham Lertsukekasem
2. Mr. Sirisak Manitkunakarn
3. Mrs. Prapasri Suchantabutr

The Board of Directors recommends proposing to the 2026 Annual General Meeting of Shareholders the re-election of the three directors retiring by rotation to serve another term. This recommendation is based on their knowledge, skills, experience, and expertise, which are valuable to the Company's operations, and their fulfillment of all qualifications and lack of disqualifications as stipulated by relevant laws. Please refer to Attachment 7 for details.

Resolution: This agenda item requires approval by a majority vote of shareholders present and voting.

Agenda 7: Consider and approve the appointment of auditors and determine their remuneration for the year 2026.

Objectives and Rationale

This is in accordance with the Public Limited Companies Act, B.E. 2535 (1992), Section 120, and the Company's Articles of Association, Article 53. The annual general meeting shall appoint the Company's auditor and determine their audit fees. An auditor who has retired is eligible for re-election. The auditor must not be a director, employee, staff or hold any position within the Company.

Audit Committee's Opinion

The Audit Committee has considered and selected DIA International Audit Co., Ltd. as the auditor for the year 2026, based on an assessment of the auditor's independence, quality and auditing capabilities, skills, knowledge, and relevant experience. The selected auditor also meets the qualifications required by the Securities and Exchange Commission ("SEC"). Therefore, the Audit Committee proposes to the shareholders' meeting for approval the appointment of Ms. Supaporn Mangjitr, Certified Public Accountant Registration No. 8125, and/or Mr. Joompoth Piratanakorn, Certified Public Accountant Registration No. 7645, and/or Mr. Apipong Luengnakthongdee, Certified Public Accountant Registration No. 12199, with auditor's remuneration for the year 2026 set at 1,300,000 baht, excluding other expenses, as detailed in Attachment 7.

Opinion of the Board of Directors

It is deemed appropriate to propose to the Annual General Meeting of Shareholders to consider and approve the appointment of DIA International Audit Company Limited as the Company's auditor, as they are approved by the Securities and Exchange Commission ("SEC") and possess expertise in auditing. The proposed auditor's remuneration for the year 2026 is set at 1,300,000 baht, a decrease of 250,000 baht from the 1,550,000 baht paid in 2025. One of the following auditors will be assigned to audit the Company's financial statements and provide an opinion as follows:

1. Ms. Suphaphorn Mangjit, Certified Public Accountant Registration No. 8125, or
2. Mr. Joompoth Priratanakorn, Certified Public Accountant, Registration No. 7645, or
3. Mr. Apipong Luengnakthongdee, Certified Public Accountant Registration No. 12199

Resolution: This agenda item requires approval by a majority vote of shareholders present and voting.

Agenda 8: Consider approving the change in the objectives of the use of IPO proceeds

Objectives and Rationale

This is in accordance with Notification of the Office of the Securities and Exchange Commission No. SorJor. 63/2561 regarding changes to the objective of the use of proceeds under the Registration Statement for Securities Offering and Draft Prospectus Article 2. If an authorized party wishes to change the objectives of the use of proceeds as disclosed in the registration statement, if such change falls under any of the following characteristics and the Board of Directors determines that such change is an immaterial change in the objectives of the use of proceeds, it shall be deemed an immaterial change in the objectives of the use of proceeds pursuant to the notification concerning the offering of newly issued shares.

(2) Use of proceeds for matters not previously disclosed in the registration statement, as per one of the following criteria:

(a) In the event that the use of proceeds related to the business disclosed in the registration statement, the change in the value of those proceeds must not exceed 30% of the proceeds from that share offering.

Opinion of the Board of Directors

It is deemed appropriate to propose to the annual general meeting of shareholders that they consider and approve the change in the objectives of the use of IPO proceeds to maximize shareholder benefit. The Company has conducted a comparative review between the construction of a new building for Mukdahan International Hospital Public Company Limited, as outlined in the prospectus, versus the alternative of renovating the existing building. Therefore, it is deemed appropriate to proceed with the renovation of the existing building instead of building a new one, as this will yield the greatest benefit with the shortest implementation timeframe. The



บริษัท โรงพยาบาลมุกดาหารอินเตอร์เนชั่นแนล จำกัด (มหาชน)
Mukdahan International Hospital Public Company Limited

construction project for Dr. Hann Hospital Company Limited will proceed as originally stated in the prospectus, with no changes.

Resolution: This agenda item requires approval by a majority vote of shareholders present and voting.

Agenda 9: Consider other matters, if applicable.

Objectives and Rationale

This is in accordance with Section 105, paragraph two of the Public Limited Company Act, which stipulates that shareholders holding at least one-third of the total issued shares may request that the meeting agenda include items beyond those listed in the meeting invitation.

Therefore, the Company cordially invites all shareholders to attend the 2026 Annual General Meeting, to be held via electronic media (E-AGM) on the date and time specified above. The meeting will be held exclusively via electronic media (E-AGM), and advance registration is required. Registration will open on April 30, 2026, at 12:30 PM. The Company will use the electronic platform as the sole method for registration, voting, and the counting of votes Please see Attachment 5 for further details.

Yours sincerely

(Mr. Boontham Lertsukekasem)

Chairman of the Board of Directors